Oxford Science Enterprises

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Founded in 2018 as a spin-out from the University of Oxford, Caristo Diagnostics develops artificial intelligence-based software for measuring coronary artery inflammation to predict heart attacks. Its flagship product, CaRi-Heart, applies advanced AI algorithms to routine cardiac CT scans, visualizing and quantifying coronary inflammation, which is the root cause of coronary artery disease. The company's patented Fat Attenuation Index (FAI) biomarker indicates a patient's risk relative to peers, while CaRi-Heart Risk assesses absolute 8-year fatal heart attack risk. Caristo Diagnostics has attracted over £23 million in venture capital investment and its technology is CE Mark certified.

Mind Foundry Limited, incorporated in 2015 and based in Oxford, United Kingdom, develops enterprise software that enables organizations to extract valuable insights from their data. As an Oxford University company founded by leading experts in artificial intelligence and machine learning, Mind Foundry focuses on creating Responsible AI solutions designed to address significant real-world challenges across various sectors, including insurance, infrastructure, and defense. Their AI platform leverages advanced machine learning and algorithmic modeling techniques to help organizations tackle issues such as insurance fraud detection and complex signal processing. By promoting the responsible and transparent use of AI, Mind Foundry aims to foster collaboration between humans and artificial intelligence to address pressing global problems.

Osler Diagnostics is a UK-based company focused on providing accessible and accurate health diagnostics. Founded in 2017 as a spin-off from the University of Oxford, the company has leveraged extensive research in portable diagnostic technologies, originally stemming from the development of the blood glucose sensor. Its flagship product, the Osler Origin, is a portable laboratory capable of delivering lab-quality diagnostics anytime and anywhere, enabling individuals to conduct tests for a variety of health biomarkers using just a drop of blood. This innovative approach aims to decentralize healthcare, making it easier for users to monitor their health and make informed decisions, ultimately supporting healthier and longer lives. Osler Diagnostics is headquartered in Oxford, UK, and aims to serve all major healthcare settings globally.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

ORCA Computing develops a photonic quantum computer designed to be scalable and flexible. Founded in 2019 and based in Oxford, United Kingdom, the company focuses on a photonic processor that uses quantum memories to store, synchronize, and buffer quantum operations, improving performance. Its modular, optical fiber–based architecture relies on telecoms photonics and off‑the‑shelf fiber and optical components to create a rack‑mounted platform. By exploiting photonic degrees of freedom, ORCA Computing aims to unlock new applications and accelerate innovation across industries.

BibliU operates a digital platform that provides colleges and universities with managed access to millions of textbooks and academic resources. It offers automation tools, analytics, and offline support, enhancing student learning efficiency.

MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was spun out from the University of Oxford in 2017. The company focuses on developing innovative agricultural technologies aimed at enhancing sustainable crop systems. Led by Professor Liam Dolan, FRS, MoA Technology employs a unique approach to facilitate the production of healthy food, thereby supporting farmers in their efforts to cultivate crops sustainably.

First Light Fusion Limited is a UK-based company that specializes in researching advanced implosion processes aimed at electricity generation through inertial confinement fusion. Founded in 2011 as a spin-out from the University of Oxford, the company focuses on harnessing fundamental physics to explore various innovative energy generation methods. It employs a team of engineers and physicists who engage in theoretical analysis, detailed numerical simulations, and experimental validation to develop new energy sources. First Light Fusion collaborates closely with several academic institutions, including the University of Oxford, Warwick University, University College London, and Imperial College London. The company, originally named Oxyntix Ltd., rebranded in June 2014 to reflect its focus on fusion energy research.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.

Founded in 2018 as a spin-out from the University of Oxford, Caristo Diagnostics develops artificial intelligence-based software for measuring coronary artery inflammation to predict heart attacks. Its flagship product, CaRi-Heart, applies advanced AI algorithms to routine cardiac CT scans, visualizing and quantifying coronary inflammation, which is the root cause of coronary artery disease. The company's patented Fat Attenuation Index (FAI) biomarker indicates a patient's risk relative to peers, while CaRi-Heart Risk assesses absolute 8-year fatal heart attack risk. Caristo Diagnostics has attracted over £23 million in venture capital investment and its technology is CE Mark certified.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

DJS Antibodies Ltd is a biotechnology company based in Bicester, United Kingdom, established in 2014. The company focuses on the design and discovery of novel therapeutic monoclonal antibodies specifically targeting G-protein-coupled receptors (GPCRs). DJS Antibodies aims to develop innovative therapeutics for chronic inflammatory diseases by utilizing its advanced technology to create first-in-class antibody therapeutics for previously challenging disease targets. By specializing in the research and discovery of functional antibodies against complex protein targets that have eluded traditional drug discovery efforts, DJS Antibodies endeavors to provide effective treatments for diseases that are currently considered undruggable and untreatable.

ORCA Computing develops a photonic quantum computer designed to be scalable and flexible. Founded in 2019 and based in Oxford, United Kingdom, the company focuses on a photonic processor that uses quantum memories to store, synchronize, and buffer quantum operations, improving performance. Its modular, optical fiber–based architecture relies on telecoms photonics and off‑the‑shelf fiber and optical components to create a rack‑mounted platform. By exploiting photonic degrees of freedom, ORCA Computing aims to unlock new applications and accelerate innovation across industries.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

BibliU operates a digital platform that provides colleges and universities with managed access to millions of textbooks and academic resources. It offers automation tools, analytics, and offline support, enhancing student learning efficiency.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was spun out from the University of Oxford in 2017. The company focuses on developing innovative agricultural technologies aimed at enhancing sustainable crop systems. Led by Professor Liam Dolan, FRS, MoA Technology employs a unique approach to facilitate the production of healthy food, thereby supporting farmers in their efforts to cultivate crops sustainably.

Oxford Semantic Technologies is a company founded in 2017 as a spin-out from the University of Oxford, specializing in the development of RDFox, an advanced knowledge graph and semantic reasoning engine. The company emerged from research initiated in 2011 at the University’s Computer Science Department, aimed at creating a high-performance solution for data-intensive applications. RDFox leverages patented modern computing techniques to provide rapid responses to complex queries, thus enabling enterprise applications for various prestigious partners. The engine is designed to harness the capabilities of modern multi-core architectures, simplifying the querying process for domain experts and reducing reliance on IT specialists. Additionally, RDFox includes features that explain how answers to queries are derived, enhancing clients' ability to validate their results and ensuring confidence in the insights generated.

Covatic develops broadcast personalization software and a consumer insights platform that enables on-device personalization for applications. Incorporated in 2016, the company is based in Birmingham, United Kingdom, with an additional office in London. Its platform provides an on-device software development kit that leverages trusted first-party and offline consented data to create contextual audience segments, helping media companies deliver relevant advertising while strengthening user trust and complying with privacy regulations.

Founded in 2018 as a spin-out from the University of Oxford, Caristo Diagnostics develops artificial intelligence-based software for measuring coronary artery inflammation to predict heart attacks. Its flagship product, CaRi-Heart, applies advanced AI algorithms to routine cardiac CT scans, visualizing and quantifying coronary inflammation, which is the root cause of coronary artery disease. The company's patented Fat Attenuation Index (FAI) biomarker indicates a patient's risk relative to peers, while CaRi-Heart Risk assesses absolute 8-year fatal heart attack risk. Caristo Diagnostics has attracted over £23 million in venture capital investment and its technology is CE Mark certified.

BioBeats, established in 2012 and headquartered in London, specializes in digital health solutions for personal wellness. The company leverages artificial intelligence and real-time data from smartphones and wearables to tackle global mental health challenges. By fusing research from the University of Oxford, BioBeats creates AI products that track neurological and physiological correlates to psychological progress, predict disorder onset, and provide personalized support. Their psychological wellness application calculates a baseline wellbeing score and offers insights into stress responses, enabling users to identify harmful patterns and improve their overall mental health.

BibliU operates a digital platform that provides colleges and universities with managed access to millions of textbooks and academic resources. It offers automation tools, analytics, and offline support, enhancing student learning efficiency.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

First Light Fusion Limited is a UK-based company that specializes in researching advanced implosion processes aimed at electricity generation through inertial confinement fusion. Founded in 2011 as a spin-out from the University of Oxford, the company focuses on harnessing fundamental physics to explore various innovative energy generation methods. It employs a team of engineers and physicists who engage in theoretical analysis, detailed numerical simulations, and experimental validation to develop new energy sources. First Light Fusion collaborates closely with several academic institutions, including the University of Oxford, Warwick University, University College London, and Imperial College London. The company, originally named Oxyntix Ltd., rebranded in June 2014 to reflect its focus on fusion energy research.

Mind Foundry Limited, incorporated in 2015 and based in Oxford, United Kingdom, develops enterprise software that enables organizations to extract valuable insights from their data. As an Oxford University company founded by leading experts in artificial intelligence and machine learning, Mind Foundry focuses on creating Responsible AI solutions designed to address significant real-world challenges across various sectors, including insurance, infrastructure, and defense. Their AI platform leverages advanced machine learning and algorithmic modeling techniques to help organizations tackle issues such as insurance fraud detection and complex signal processing. By promoting the responsible and transparent use of AI, Mind Foundry aims to foster collaboration between humans and artificial intelligence to address pressing global problems.

Inkpath Limited is a technology company that specializes in a skill tracking software platform aimed at enhancing personal and professional development for university students and administrators. Founded in 2015 and based in Thame, United Kingdom, the platform allows users to set goals, manage courses, track attendance and feedback, and monitor their development progress. Through its user-friendly smartphone application, students can access tailored training opportunities, record their achievements, and receive continuous, data-driven feedback. This comprehensive solution not only supports student engagement but also provides valuable insights to university administrators, ultimately helping students improve their employability upon graduation.

DiffBlue is a software company that develops AI-powered automated testing and code automation tools. It automates coding tasks such as generating unit tests, bug fixing, refactoring, translating code between languages, and producing original code to meet specifications. Its automated testing software for Java creates fully autonomous unit tests, maintains regression tests, and provides insights into test coverage, code testability, complexity and dependencies. The technology uses reinforcement learning to write tests that compile, run, and detect bugs, reducing manual testing effort and accelerating software development. In addition to test generation, DiffBlue offers security testing capabilities to identify and fix exploits. DiffBlue originated as a spin-out of the University of Oxford's AI research group and is based in Oxford, United Kingdom.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.

Oxford Semantic Technologies is a company founded in 2017 as a spin-out from the University of Oxford, specializing in the development of RDFox, an advanced knowledge graph and semantic reasoning engine. The company emerged from research initiated in 2011 at the University’s Computer Science Department, aimed at creating a high-performance solution for data-intensive applications. RDFox leverages patented modern computing techniques to provide rapid responses to complex queries, thus enabling enterprise applications for various prestigious partners. The engine is designed to harness the capabilities of modern multi-core architectures, simplifying the querying process for domain experts and reducing reliance on IT specialists. Additionally, RDFox includes features that explain how answers to queries are derived, enhancing clients' ability to validate their results and ensuring confidence in the insights generated.

Pro-Mapp Health is a company focused on improving patient care through the intelligent application of patient-reported outcome measures. Originating as a spin-out from Oxford University, Pro-Mapp has developed software that specifically manages orthopedic care pathways, facilitating the monitoring of safety and the generation of reports on surgical and clinical outcomes. This technology-driven approach ensures that patients receiving treatments for procedures such as hip, knee, and shoulder surgeries benefit from ongoing evaluations of their health outcomes. Pro-Mapp's foundation in clinical expertise and academic research positions it at the forefront of enhancing healthcare practices and patient experiences.

BibliU operates a digital platform that provides colleges and universities with managed access to millions of textbooks and academic resources. It offers automation tools, analytics, and offline support, enhancing student learning efficiency.

Covatic develops broadcast personalization software and a consumer insights platform that enables on-device personalization for applications. Incorporated in 2016, the company is based in Birmingham, United Kingdom, with an additional office in London. Its platform provides an on-device software development kit that leverages trusted first-party and offline consented data to create contextual audience segments, helping media companies deliver relevant advertising while strengthening user trust and complying with privacy regulations.

DJS Antibodies Ltd is a biotechnology company based in Bicester, United Kingdom, established in 2014. The company focuses on the design and discovery of novel therapeutic monoclonal antibodies specifically targeting G-protein-coupled receptors (GPCRs). DJS Antibodies aims to develop innovative therapeutics for chronic inflammatory diseases by utilizing its advanced technology to create first-in-class antibody therapeutics for previously challenging disease targets. By specializing in the research and discovery of functional antibodies against complex protein targets that have eluded traditional drug discovery efforts, DJS Antibodies endeavors to provide effective treatments for diseases that are currently considered undruggable and untreatable.

Oxford Impedance Diagnostics Limited is a company based in Oxford, United Kingdom, that focuses on researching, designing, and marketing diagnostic tests specifically aimed at measuring clinical biomarkers. Founded in 2016, the company's products are intended to facilitate personalized medicine, enhance early risk detection, and improve the diagnosis and management of diseases. By providing innovative diagnostic solutions, Oxford Impedance Diagnostics seeks to reduce healthcare costs while improving patient outcomes.

Osler Diagnostics is a UK-based company focused on providing accessible and accurate health diagnostics. Founded in 2017 as a spin-off from the University of Oxford, the company has leveraged extensive research in portable diagnostic technologies, originally stemming from the development of the blood glucose sensor. Its flagship product, the Osler Origin, is a portable laboratory capable of delivering lab-quality diagnostics anytime and anywhere, enabling individuals to conduct tests for a variety of health biomarkers using just a drop of blood. This innovative approach aims to decentralize healthcare, making it easier for users to monitor their health and make informed decisions, ultimately supporting healthier and longer lives. Osler Diagnostics is headquartered in Oxford, UK, and aims to serve all major healthcare settings globally.

DiffBlue is a software company that develops AI-powered automated testing and code automation tools. It automates coding tasks such as generating unit tests, bug fixing, refactoring, translating code between languages, and producing original code to meet specifications. Its automated testing software for Java creates fully autonomous unit tests, maintains regression tests, and provides insights into test coverage, code testability, complexity and dependencies. The technology uses reinforcement learning to write tests that compile, run, and detect bugs, reducing manual testing effort and accelerating software development. In addition to test generation, DiffBlue offers security testing capabilities to identify and fix exploits. DiffBlue originated as a spin-out of the University of Oxford's AI research group and is based in Oxford, United Kingdom.

Mind Foundry Limited, incorporated in 2015 and based in Oxford, United Kingdom, develops enterprise software that enables organizations to extract valuable insights from their data. As an Oxford University company founded by leading experts in artificial intelligence and machine learning, Mind Foundry focuses on creating Responsible AI solutions designed to address significant real-world challenges across various sectors, including insurance, infrastructure, and defense. Their AI platform leverages advanced machine learning and algorithmic modeling techniques to help organizations tackle issues such as insurance fraud detection and complex signal processing. By promoting the responsible and transparent use of AI, Mind Foundry aims to foster collaboration between humans and artificial intelligence to address pressing global problems.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Oxtex Limited is a medical device company that originated as a spinout from the University of Oxford, specializing in the development of anisotropic self-inflating tissue expanders. Utilizing advanced hydrogel technology, Oxtex offers innovative solutions for soft tissue expansion that cater to various clinical needs in reconstructive plastic surgery and restorative dentistry. The company's tissue expanders are designed for diverse applications, including scar revision, tumor removal, and correction of birth defects. By providing these novel devices, Oxtex aims to enhance surgical outcomes, allowing surgeons to perform procedures that minimize scarring and improve recovery for patients.